A citation-based method for searching scientific literature

Aubin Michalon, Michael Sidorov, Theresa M Ballard, Laurence Ozmen, Will Spooren, Joseph G Wettstein, Georg Jaeschke, Mark F Bear, Lothar Lindemann. Neuron 2012
Times Cited: 348







List of co-cited articles
1474 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Correction of fragile X syndrome in mice.
Gül Dölen, Emily Osterweil, B S Shankaranarayana Rao, Gordon B Smith, Benjamin D Auerbach, Sumantra Chattarji, Mark F Bear. Neuron 2007
689
48

The mGluR theory of fragile X mental retardation.
Mark F Bear, Kimberly M Huber, Stephen T Warren. Trends Neurosci 2004
44

Altered synaptic plasticity in a mouse model of fragile X mental retardation.
Kimberly M Huber, Sean M Gallagher, Stephen T Warren, Mark F Bear. Proc Natl Acad Sci U S A 2002
963
33

FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism.
Jennifer C Darnell, Sarah J Van Driesche, Chaolin Zhang, Ka Ying Sharon Hung, Aldo Mele, Claire E Fraser, Elizabeth F Stone, Cynthia Chen, John J Fak, Sung Wook Chi,[...]. Cell 2011
30


Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.
A J Verkerk, M Pieretti, J S Sutcliffe, Y H Fu, D P Kuhl, A Pizzuti, O Reiner, S Richards, M F Victoria, F P Zhang. Cell 1991
25

Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.
Emily K Osterweil, Shih-Chieh Chuang, Alexander A Chubykin, Michael Sidorov, Riccardo Bianchi, Robert K S Wong, Mark F Bear. Neuron 2013
155
22

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.
Elizabeth M Berry-Kravis, Lothar Lindemann, Aia E Jønch, George Apostol, Mark F Bear, Randall L Carpenter, Jacqueline N Crawley, Aurore Curie, Vincent Des Portes, Farah Hossain,[...]. Nat Rev Drug Discov 2018
154
21

Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.
Aditi Bhattacharya, Hanoch Kaphzan, Amanda C Alvarez-Dieppa, Jaclyn P Murphy, Philippe Pierre, Eric Klann. Neuron 2012
209
18

Metformin ameliorates core deficits in a mouse model of fragile X syndrome.
Ilse Gantois, Arkady Khoutorsky, Jelena Popic, Argel Aguilar-Valles, Erika Freemantle, Ruifeng Cao, Vijendra Sharma, Tine Pooters, Anmol Nagpal, Agnieszka Skalecka,[...]. Nat Med 2017
105
18

Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.
Christina Henderson, Lasani Wijetunge, Mika Nakamoto Kinoshita, Matthew Shumway, Rebecca S Hammond, Friso R Postma, Christopher Brynczka, Roger Rush, Alexia Thomas, Richard Paylor,[...]. Sci Transl Med 2012
175
17

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
Q J Yan, M Rammal, M Tranfaglia, R P Bauchwitz. Neuropharmacology 2005
392
17

Mutations causing syndromic autism define an axis of synaptic pathophysiology.
Benjamin D Auerbach, Emily K Osterweil, Mark F Bear. Nature 2011
419
16


Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.
Xinglong Wang, Mike Snape, Eric Klann, Jeremy G Stone, Avneet Singh, Robert B Petersen, Rudy J Castellani, Gemma Casadesus, Mark A Smith, Xiongwei Zhu. J Neurochem 2012
52
28

Dysregulation of mTOR signaling in fragile X syndrome.
Ali Sharma, Charles A Hoeffer, Yukihiro Takayasu, Takahiro Miyawaki, Sean M McBride, Eric Klann, R Suzanne Zukin. J Neurosci 2010
397
15

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
Eriene A Youssef, Elizabeth Berry-Kravis, Christian Czech, Randi J Hagerman, David Hessl, Chin Y Wong, Michael Rabbia, Dennis Deptula, Amy John, Russell Kinch,[...]. Neuropsychopharmacology 2018
68
22

Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.
Christina Gross, Mika Nakamoto, Xiaodi Yao, Chi-Bun Chan, So Y Yim, Keqiang Ye, Stephen T Warren, Gary J Bassell. J Neurosci 2010
185
14

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
Elizabeth Berry-Kravis, Vincent Des Portes, Randi Hagerman, Sébastien Jacquemont, Perrine Charles, Jeannie Visootsak, Marc Brinkman, Karin Rerat, Barbara Koumaras, Liansheng Zhu,[...]. Sci Transl Med 2016
152
14

Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.
Elizabeth M Berry-Kravis, David Hessl, Barbara Rathmell, Peter Zarevics, Maryann Cherubini, Karen Walton-Bowen, Yi Mu, Danh V Nguyen, Joseph Gonzalez-Heydrich, Paul P Wang,[...]. Sci Transl Med 2012
226
13

Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.
Daman Kumari, Aditi Bhattacharya, Jeffrey Nadel, Kristen Moulton, Nicole M Zeak, Anne Glicksman, Carl Dobkin, David J Brick, Philip H Schwartz, Carolyn B Smith,[...]. Hum Mutat 2014
43
30

Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
T V Bilousova, L Dansie, M Ngo, J Aye, J R Charles, D W Ethell, I M Ethell. J Med Genet 2009
317
13

Modeling fragile X syndrome in the Fmr1 knockout mouse.
Tatiana M Kazdoba, Prescott T Leach, Jill L Silverman, Jacqueline N Crawley. Intractable Rare Dis Res 2014
123
13

Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.
Bridget M Dolan, Sergio G Duron, David A Campbell, Benedikt Vollrath, B S Shankaranarayana Rao, Hui-Yeon Ko, Gregory G Lin, Arvind Govindarajan, Se-Young Choi, Susumu Tonegawa. Proc Natl Acad Sci U S A 2013
143
13

Absence of expression of the FMR-1 gene in fragile X syndrome.
M Pieretti, F P Zhang, Y H Fu, S T Warren, B A Oostra, C T Caskey, D L Nelson. Cell 1991
12

A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.
Mary Jacena S Leigh, Danh V Nguyen, Yi Mu, Tri I Winarni, Andrea Schneider, Tasleem Chechi, Jonathan Polussa, Paul Doucet, Flora Tassone, Susan M Rivera,[...]. J Dev Behav Pediatr 2013
155
12

Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet's signaling cascades as new outcome measures in clinical trials.
David Pellerin, Artuela Çaku, Mathieu Fradet, Paméla Bouvier, Jean Dubé, François Corbin. Biomarkers 2016
25
48

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
Lothar Lindemann, Georg Jaeschke, Aubin Michalon, Eric Vieira, Michael Honer, Will Spooren, Richard Porter, Thomas Hartung, Sabine Kolczewski, Bernd Büttelmann,[...]. J Pharmacol Exp Ther 2011
77
15

Arbaclofen in fragile X syndrome: results of phase 3 trials.
Elizabeth Berry-Kravis, Randi Hagerman, Jeannie Visootsak, Dejan Budimirovic, Walter E Kaufmann, Maryann Cherubini, Peter Zarevics, Karen Walton-Bowen, Paul Wang, Mark F Bear,[...]. J Neurodev Disord 2017
90
13

Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse.
Mei Qin, Julia Kang, Thomas V Burlin, Chunhui Jiang, Carolyn Beebe Smith. J Neurosci 2005
169
12

Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome.
Jose Luis Olmos-Serrano, Scott M Paluszkiewicz, Brandon S Martin, Walter E Kaufmann, Joshua G Corbin, Molly M Huntsman. J Neurosci 2010
218
11


Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome.
Giulia Curia, Thomas Papouin, Philippe Séguéla, Massimo Avoli. Cereb Cortex 2009
165
11

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
Sebastian H Scharf, Georg Jaeschke, Joseph G Wettstein, Lothar Lindemann. Curr Opin Pharmacol 2015
69
15

Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.
Artuela Çaku, David Pellerin, Paméla Bouvier, Emilie Riou, Francois Corbin. Am J Med Genet A 2014
45
24

Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice.
Ilse Gantois, Andreea S Pop, Celine E F de Esch, Ronald A M Buijsen, Tine Pooters, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Ben A Oostra, Rudi D'Hooge, Rob Willemsen. Behav Brain Res 2013
68
16

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
Sébastien Jacquemont, Aurore Curie, Vincent des Portes, Maria Giulia Torrioli, Elizabeth Berry-Kravis, Randi J Hagerman, Feliciano J Ramos, Kim Cornish, Yunsheng He, Charles Paulding,[...]. Sci Transl Med 2011
256
11

Shank3 mutant mice display autistic-like behaviours and striatal dysfunction.
João Peça, Cátia Feliciano, Jonathan T Ting, Wenting Wang, Michael F Wells, Talaignair N Venkatraman, Christopher D Lascola, Zhanyan Fu, Guoping Feng. Nature 2011
856
11

Molecular mechanisms of fragile X syndrome: a twenty-year perspective.
Michael R Santoro, Steven M Bray, Stephen T Warren. Annu Rev Pathol 2012
352
10


Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.
C A Hoeffer, E Sanchez, R J Hagerman, Y Mu, D V Nguyen, H Wong, A M Whelan, R S Zukin, E Klann, F Tassone. Genes Brain Behav 2012
128
10

Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome.
Jennifer A Ronesi, Katie A Collins, Seth A Hays, Nien-Pei Tsai, Weirui Guo, Shari G Birnbaum, Jia-Hua Hu, Paul F Worley, Jay R Gibson, Kimberly M Huber. Nat Neurosci 2012
178
10

Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome.
S A Musumeci, P Bosco, G Calabrese, C Bakker, G B De Sarro, M Elia, R Ferri, B A Oostra. Epilepsia 2000
195
10

FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels.
Pan-Yue Deng, Ziv Rotman, Jay A Blundon, Yongcheol Cho, Jianmin Cui, Valeria Cavalli, Stanislav S Zakharenko, Vitaly A Klyachko. Neuron 2013
212
10

Altered Neuronal and Circuit Excitability in Fragile X Syndrome.
Anis Contractor, Vitaly A Klyachko, Carlos Portera-Cailliau. Neuron 2015
202
10


A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.
E Berry-Kravis, D Hessl, S Coffey, C Hervey, A Schneider, J Yuhas, J Hutchison, M Snape, M Tranfaglia, D V Nguyen,[...]. J Med Genet 2009
265
10

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.
Lothar Lindemann, Richard H Porter, Sebastian H Scharf, Basil Kuennecke, Andreas Bruns, Markus von Kienlin, Anthony C Harrison, Axel Paehler, Christoph Funk, Andreas Gloge,[...]. J Pharmacol Exp Ther 2015
70
14

Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function.
Hyejung Won, Hye-Ryeon Lee, Heon Yung Gee, Won Mah, Jae-Ick Kim, Jiseok Lee, Seungmin Ha, Changuk Chung, Eun Suk Jung, Yi Sul Cho,[...]. Nature 2012
437
10

Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.